Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.

Abstract

Poorly differentiated neuroendocrine carcinoma is a rare malignancy that remains a challenge to treat. Poorly differentiated neuroendocrine carcinoma occurs at an incidence of 2% annually in United States. The current standard of care is based largely upon retrospective data. There remains a need for large prospective cooperative group trials in the management of poorly differentiated neuroendocrine carcinoma. In this paper, we will review abstract #e15096 (Paclitaxel, carboplatin, and etoposide (TCE) in advanced poorly differentiated neuroendocrine carcinoma) by Loeffler et al. and #e15071 (Poorly differentiated neuroendocrine carcinoma (NEC G3): prognostic factors and potential novel targets) by Heetfeld et al. presented at the 2013 ASCO Annual Meeting highlighting treatment options in first and second lines for poorly differentiated neuroendocrine carcinoma.

• Authors: Anumeha Gupta, Marvin Duque, Muhammad Wasif Saif
• Journal: JOP : Journal of the pancreas (JOP) Vol. 14 Issue 4 Pg. 381-3 (Jul 10 2013) ISSN: 1590-8577 [Electronic] Italy
• PMID: 23846932 (Publication Type: Journal Article, Review)

Chemical References

• Etoposide
• Carboplatin
• MTOR protein, human
• Receptor, IGF Type 1
• TOR Serine-Threonine Kinases
• Paclitaxel

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage)
• Carcinoma, Neuroendocrine (drug therapy, metabolism, pathology)
• Etoposide (administration & dosage)
• Humans
• Paclitaxel (administration & dosage)
• Pancreatic Neoplasms (drug therapy, metabolism, pathology)
• Receptor, IGF Type 1 (metabolism)
• TOR Serine-Threonine Kinases (metabolism)
• Treatment Outcome